Baseline characteristics of 120 patients who underwent screening for precision prostatectomy with either TR biopsy or TP biopsy
| TR biopsy (n=60) | TP biopsy (n=60) | |
| Age (years), median (IQR) | 57.5 (53.0–64.0) | 62.0 (57.0–66.3) |
| BMI (kg/m2), median (IQR) | 28.4 (26.0–31.0) | 28.5 (25.2–30.9) |
| Race, n (%) | ||
| African–American | 8 (13) | 16 (27) |
| Asian | 1 (2) | 1 (2) |
| Hispanic | 2 (3) | 1 (2) |
| Caucasian | 45 (75) | 37 (62) |
| Other/unknown | 4 (7) | 5 (8) |
| Preoperative PSA (ng/mL), median (IQR) | 5.4 (3.8–6.3) | 5.9 (4.6–8.2) |
| Biopsy Gleason group, n (%) | ||
| 1 | 19 (31) | 8 (13) |
| 2 | 37 (62) | 34 (57) |
| 3 | 4 (7) | 18 (30) |
| Clinical T stage, n (%) | ||
| T1 | 41 (68) | 55 (92) |
| T2 | 19 (32) | 4 (7) |
| T3 | 0 (0) | 1 (2) |
| Clinical National Comprehensive Cancer Network (NCCN) risk, n (%) | ||
| Low | 19 (32) | 8 (13) |
| Intermediate | 40 (67) | 52 (87) |
| High | 1 (2) | 0 (0) |
BMI, body mass index; PSA, prostate-specific antigen; TP, transperineal; TR, transrectal.